199 related articles for article (PubMed ID: 20663804)
1. Restoring circadian rhythms: a new way to successfully manage depression.
Gorwood P
J Psychopharmacol; 2010 Aug; 24(2 Suppl):15-9. PubMed ID: 20663804
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
3. The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.
Llorca PM
J Psychopharmacol; 2010 Aug; 24(2 Suppl):21-6. PubMed ID: 20663805
[TBL] [Abstract][Full Text] [Related]
4. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
Jakovljević M
Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
[TBL] [Abstract][Full Text] [Related]
5. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
6. Addressing circadian rhythm disturbances in depressed patients.
Lam RW
J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
[TBL] [Abstract][Full Text] [Related]
7. The importance of early symptom relief in antidepressant treatment: focus on agomelatine.
Lam RW
J Psychopharmacol; 2010 Aug; 24(2 Suppl):27-30. PubMed ID: 20663806
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
9. The preclinical discovery and development of agomelatine for the treatment of depression.
Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
[TBL] [Abstract][Full Text] [Related]
10. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine: a narrative review.
Demyttenaere K
Eur Neuropsychopharmacol; 2011 Sep; 21 Suppl 4():S703-9. PubMed ID: 21835598
[TBL] [Abstract][Full Text] [Related]
12. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
Rouillon F
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
[TBL] [Abstract][Full Text] [Related]
14. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
[TBL] [Abstract][Full Text] [Related]
16. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
17. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
18. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
19. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
Kennedy SH; Rizvi SJ
CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
[TBL] [Abstract][Full Text] [Related]
20. Clinical studies on the efficacy of agomelatine on depressive symptoms.
Goodwin GM
CNS Drugs; 2009; 23 Suppl 2():35-9. PubMed ID: 19708724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
